BIGG

Resultados: 9

Compounded bioidentical menopausal hormone therapy ACOG clinical consensus nº 6

Obstet. gynecol; 142 (5), 2023
Many compounding pharmacies use the phrase “bioidentical hormone” as a marketing term to imply that these preparations are natural and, thus, safer and more effective than U.S. Food and Drug Administration (FDA)–approved menopausal medications that use bioidentical or synthetic hormones or both. Ho...

Directive clinique No 422b: ménopause et santé génito-urinaire

j obstet gynaecol can; 21 (), 2021
Proposer des stratégies fondées sur les plus récentes données publiées pour améliorer les soins aux femmes ménopausées ou en périménopause. Les femmes ménopausées ou en périménopause. La population cible bénéficiera des plus récentes données scientifiques publiées communiquées par leu...

Directive clinique n° 422c: ménopause: humeur, sommeil et cognition
Guideline No. 422c: Menopause: Mood, Sleep, and Cognition

j obstet gynaecol can; 21 (), 2021
Proposer des stratégies fondées sur les plus récentes données publiées pour améliorer les soins aux femmes ménopausées ou en périménopause. Les femmes ménopausées ou en périménopause. La population cible bénéficiera des plus récentes données scientifiques publiées communiquées par leu...

Guideline No. 422d: Menopause and Sexuality

j obstet gynaecol can; 21 (), 2021
Provide strategies for improving the care of perimenopausal and postmenopausal women based on the most recent published evidence. Perimenopausal and postmenopausal women. Target population will benefit from the most recent published scientific evidence provided via the information from their health care ...

Guideline No. 422b: Menopause and Genitourinary Health

j obstet gynaecol can; 21 (), 2021
Provide strategies for improving the care of perimenopausal and postmenopausal women based on the most recent published evidence. Perimenopausal and postmenopausal women. Target population will benefit from the most recent published scientific evidence provided via the information from their health care ...

Guideline No. 422a: Menopause: Vasomotor Symptoms, Prescription Therapeutic Agents, Complementary and Alternative Medicine, Nutrition, and Lifestyle

j obstet gynaecol can; 21 (), 2021
Provide strategies for improving the care of perimenopausal and postmenopausal women based on the most recent published evidence. Perimenopausal and postmenopausal women. Target population will benefit from the most recent published scientific evidence provided via the information from their health care ...

Menopause: diagnosis and management

This guideline covers the diagnosis and management of menopause, including in women who have premature ovarian insufficiency. The guideline aims to improve the consistency of support and information provided to women in menopause....

Guía de práctica clínica sobre el abordaje de síntomas vasomotores y vaginales asociados a la menopausia y la postmenopausia
Clinical practice guide on the approach of vasomotor and vaginal symptoms associated with menopause and postmenopause

Esta guía pretende clarificar qué síntomas son derivados del déficit hormonal secundario a la pérdida de actividad folicular del ovario, y cuál es la eficacia y la seguridad de los tratamientos disponibles. De esta forma, se espera contribuir a la disminución de la variabilidad de la práctica cl...

Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline

J. clin. endocrinol. metab; 100 (11), 2015
OBJECTIVE: The objective of this document is to generate a practice guideline for the management and treatment of symptoms of the menopause. PARTICIPANTS: The Treatment of Symptoms of the Menopause Task Force included six experts, a methodologist, and a medical writer, all appointed by The Endocrine Soci...